Research & Development

Objectives

> To develop the product range: 

development of new forms, research into new indications, winning new international markets. E.g.: colitis caused by Clostridium difficile, Crohn’s disease, inflammatory bowel disease, etc.

> To develop innovative substances, particularly for the central nervous system, and specific competence in epileptology: 

in 2007 DIACOMIT® was granted the agreement for the 27 countries of the EU.

> To scientifically improve particular products which have been acquired:

such as STRESAM®, which has become one of the main non-benzodiazepine anxiolytics available in France, or the injectable analgesic ACUPAN®, which was purchased in 1997 and which is developing positively in the treatment of postoperative pain.

> To innovate with new pharmaceutical forms.